{"entity":{"id":"nct06081920","kind":"trial","name":"A Study of IBI363 in Subjects With Advanced Melanoma","aka":[],"tldr":"A phase 2 trial of IBI363 in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"A Study of IBI363 in Subjects With Advanced Melanoma is a phase 2 interventional study registered as NCT06081920 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2023-10-19 and due to reach its primary completion in 2028-10-19. Interventions recorded: IBI363. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06081920","url":"https://clinicaltrials.gov/study/NCT06081920"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi363"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06081920","phase":"2","setting":"A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":180,"outcomes":[]},"route":"/trials/nct06081920/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}